Unlike the m6A modulators mentioned previously, IGF2BP3 has been proven to be secreted into serum and could be a promising diagnostic and prognostic marker of prostate cancer and renal cell carcinoma.12, 13. Here, IGF2BP3 is linked to hereditary clear cell renal cell carcinoma.